In Germany, overactive bladder (OAB) syndrome affects around 6.5 million people over the age of 40.
The primary treatment consists of anticholinergics or beta-3-receptor agonists. After an anticholinergic treatment period of around 4 months, compliance is around 40%, which is probably due a larger proportion of nonresponders. One condition of an efficient medication treatment is the presence of detrusor overactivity (DO). However, the detection rate of DO during standard urodynamics is very low. The primary goal in the future is to target OAB treatment by detection of DO. Using the Wille Capsule (WiCa) in an in vitro model, DO could be detected over a time period of 72 h, which would ensure a higher compliance to the OAB treatment in a positive way.
Written by:
Wille S, Tenholte D, Cornely OA, Muthen N, Engelmann UH, Mehner J, Eminaga O, Herden J, Schumacher P, Paas J. Are you the author?
Klinik und Poliklinik für Urologie, Uniklinik Köln, Kerpenerstr., 50931, Köln, Deutschland.
Reference: Urologe A. 2014 Nov 20. Epub ahead of print.
doi: 10.1007/s00120-014-3629-7
PubMed Abstract
PMID: 25406371
Article in German.